On this page
Back to topBillionToOne BLLN
BillionToOne listed on Nasdaq on 6 Nov 2025 and is not in the S&P 500. It is worth $4.3 billion. Its price history starts on 7 Nov 2025. Its board has 7 directors, 5 of them independent. 6 other officers are on file. At 30 Jun 2026, Adams Street Partners was its largest institutional holder, with 3.7% of the company.
- Chair and CEO
- Oguzhan Atay
- Listed
- 6 Nov 2025 on Nasdaq
- Headquarters
- Menlo Park, CA
- Market cap
- $4.3B
- 19 Nov 2026 close
- Price to sales
- 14.1
- Market cap over revenue
Financials
Financial history
Twelve months to 30 Sep 2026, from BillionToOne's quarterly filings.
Quarters since Sep 2024
- Revenue
- $437M
- Up 72% on the year before
- Net income
- $49M
- 11.3% of revenue
- Free cash flow
- $34M
- Operating cash flow less capital spending
- P/E
- 87.2
- Market cap over net income
Quarterly results
Each quarter's revenue, net income and free cash flow.
Sep 2024 to Sep 2026
| Quarter | Revenue | Net income |
|---|---|---|
| Sep 2026 | $123M | $17M |
| Jun 2026 | $109M | $8M |
| Mar 2026 | $108M | $18M |
| Dec 2025 | $96M | $6M |
| Sep 2025 | $84M | $6M |
| Jun 2025 | $67M | $-246,000 |
| Mar 2025 | $59M | $-4M |
| Dec 2024 | $45M | $-11M |
| Sep 2024 | $38M | $-15M |
Revenue breakdown
BillionToOne's $123M of revenue, as its quarterly report splits it. Parts that are not a business, such as sales between segments, can be negative.
Quarter to Sep 2026
| Split by | Part | Revenue |
|---|---|---|
| Product | Prenatal | $104M |
| Product | Oncology | $17M |
| Product | Clinical trial support and other services | $2M |
BillionToOne's market cap since November 2025
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $5.0B |
| 26 Dec 2025 | $4.1B |
Download BillionToOne's data as JSON, with the weekly market caps in billions of dollars from 7 Nov 2025.
Board and leadership
Board and officers
Board from the proxy filed 21 Apr 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (7) | |||||
| Oguzhan AtayChair and CEONot independent · since 2016 | |||||
| Thomas S. BremnerDirectorIndependent · since 2022 · Audit, CompensationPartner, Growth Equity team, Adams Street Partners, LLC | |||||
| Firat IleriLead Independent DirectorIndependent · since 2019 · CompensationManaging Partner, Hummingbird Ventures | |||||
| Krishna Kittu KolluriDirectorIndependent · since 2019 · Compensation (chair)Founding Partner, Neotribe Ventures | |||||
| Anthony PaganoDirectorIndependent · since 2026 · Audit (chair)Chief Financial Officer and Executive Vice President, Genmab | |||||
| Akshay RaiDirectorIndependent · since 2024 · AuditU.S. Healthcare Investments Lead, Premji Invest | |||||
| David TsaoChief Technology OfficerNot independent · since 2016 | |||||
| Officers (6) | |||||
| Ross TaylorChief Financial OfficerLast filed 12 Nov 2025 | |||||
| John Roderick ten BoschSVP of Laboratory OperationsLast filed 28 Sep 2026 | |||||
| Nancy JoAnn JohnsonSenior Vice President of Sales and Commercial OperationsLast filed 20 Jul 2026 | |||||
| John ListerChief Administrative OfficerLast filed 12 Nov 2025 | |||||
| Thomas P. LynchGeneral Counsel, Chief Compliance Officer and SecretaryLast filed 21 Sep 2026 | |||||
| Shan Riku SakakibaraChief Product OfficerLast filed 14 Sep 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of BillionToOne. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $58.5 million of stock in 40 sales and made no open-market purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 2 Nov 2026Sale | Oguzhan AtayChairman and CEO | $3.3M |
| 2 Nov 2026Sale | David TsaoChief Technology Officer | $2.2M |
| 2 Nov 2026Sale | John Roderick ten BoschSVP of Laboratory Operations | $321K |
| 28 Oct 2026Sale | Oguzhan AtayChairman and CEO | $1.3M |
| 15 Oct 2026Sale | Oguzhan AtayChairman and CEO | $516K |
| 14 Oct 2026Sale | Oguzhan AtayChairman and CEO | $574K |
| 12 Oct 2026Sale | Oguzhan AtayChairman and CEO | $1.8M |
| 5 Oct 2026Sale | David TsaoChief Technology Officer | $2.2M |
| 5 Oct 2026Sale | John Roderick ten BoschSVP of Laboratory Operations | $298K |
| 28 Sep 2026Sale | Oguzhan AtayChairman and CEO | $1.3M |
Showing 10 of 40 trades
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
0 departures and 1 appointment of directors and officers and 21 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of BillionToOne's insider sales.
Events, newest first
- 2 Nov 2026 Oguzhan Atay sold $3.3MChairman and CEO
- 2 Nov 2026 David Tsao sold $2.2MChief Technology Officer
- 28 Oct 2026 Oguzhan Atay sold $1.3MChairman and CEO
- 12 Oct 2026 Oguzhan Atay sold $1.8MChairman and CEO
- 5 Oct 2026 David Tsao sold $2.2MChief Technology Officer
- 28 Sep 2026 Oguzhan Atay sold $1.3MChairman and CEO
- 17 Sep 2026 Thomas P. Lynch sold $3.9MGeneral Counsel, Chief Compliance Officer and Secretary
- 14 Sep 2026 Oguzhan Atay sold $3.0MChairman and CEO
Showing 8 of 22 events
| Date | Event | Filing |
|---|---|---|
| 2 Nov 2026 | Oguzhan Atay sold $3.3MChairman and CEO | Form 4 |
| 2 Nov 2026 | David Tsao sold $2.2MChief Technology Officer | Form 4 |
| 28 Oct 2026 | Oguzhan Atay sold $1.3MChairman and CEO | Form 4 |
| 12 Oct 2026 | Oguzhan Atay sold $1.8MChairman and CEO | Form 4 |
| 5 Oct 2026 | David Tsao sold $2.2MChief Technology Officer | Form 4 |
| 28 Sep 2026 | Oguzhan Atay sold $1.3MChairman and CEO | Form 4 |
| 17 Sep 2026 | Thomas P. Lynch sold $3.9MGeneral Counsel, Chief Compliance Officer and Secretary | Form 4 |
| 14 Sep 2026 | Oguzhan Atay sold $3.0MChairman and CEO | Form 4 |
| 9 Sep 2026 | David Tsao sold $2.0MChief Technology Officer | Form 4 |
| 8 Sep 2026 | Thomas P. Lynch sold $2.0MGeneral Counsel, Chief Compliance Officer and Secretary | Form 4 |
| 25 Aug 2026 | David Tsao sold $1.0MChief Technology Officer | Form 4 |
| 5 Aug 2026 | Oguzhan Atay sold $2.3MChairman and CEO | Form 4 |
| 3 Aug 2026 | Oguzhan Atay sold $6.2MChairman and CEO | Form 4 |
| 16 Jul 2026 | Nancy JoAnn Johnson sold $1.8MSenior Vice President of Sales and Commercial Operations | Form 4 |
| 13 Jul 2026 | David Tsao sold $2.5MChief Technology Officer | Form 4 |
| 9 Jul 2026 | Oguzhan Atay sold $1.6MChairman and CEO | Form 4 |
| 9 Jul 2026 | Shan Riku Sakakibara sold $1.0MChief Product Officer | Form 4 |
| 6 Jul 2026 | Oguzhan Atay sold $4.7MChairman and CEO | Form 4 |
| 15 Jun 2026 | David Tsao sold $2.0MChief Technology Officer | Form 4 |
| 9 Jun 2026 | Nancy JoAnn Johnson sold $1.1MSenior Vice President of Sales and Commercial Operations | Form 4 |
| 8 Jun 2026 | Oguzhan Atay sold $3.8MChairman and CEO | Form 4 |
| 9 Dec 2025 | Anthony Pagano appointedClass III director, effective 1 Jan 2026 | 8-K |
Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.